A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared With Oral Semaglutide in Adults With Type 2 Diabetes Mellitus (Eluminate-2)
A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared With Oral Semaglutide in Adults With Type 2 Diabetes Mellitus (Eluminate-2)
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron compared with oral semaglutide in adults with T2DM and increased cardiovascular risk that is inadequately managed alone or on stable treatment with other background glucose-lowering medication(s).
Inclusion Criteria:
Exclusion Criteria:
information.center@astrazeneca.com1-877-240-9479
CABA, C1120AAC, Argentina
Caba, C1128AAF, Argentina
Ciudad de Buenos Aires, C1094AAD, Argentina
Liangyugang, 222002, China
Asahikawa-shi, 070-8530, Japan
Kamakura-shi, 247-0056, Japan
Koga-shi, 306-0232, Japan
Mitaka-shi, 181-0013, Japan
Nishinomiya-shi, 663-8113, Japan
Yung Kang City, 71044, Taiwan